Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of minimal residual disease in acute leukemia after allogeneic stem cell transplant
2007-005864-28Phase 2Active
- Sponsor
- Fondazione Ricerca Trapianto di Midollo Osseo
- Start
- Mar 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of sargramostim in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), sponsored by Fondazione Ricerca Trapianto di Midollo Osseo. Primary endpoint: Primary: reduction of relapse in MRD-positive patients. Started Mar 2009; status: active.
02
Drugs
sargramostim
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2007-005864-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005864-28.